CureVac NV (WBO:CVAC) Pre-Tax Income : €-272.44 Mil (TTM As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is CureVac NV Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. CureVac NV's pretax income for the three months ended in Mar. 2024 was €-69.89 Mil. Its pretax income for the trailing twelve months (TTM) ended in Mar. 2024 was €-272.44 Mil. CureVac NV's pretax margin was -564.83%.

During the past 6 years, CureVac NV's highest Pretax Margin was -265.69%. The lowest was -574.91%. And the median was -442.06%.

CureVac NV Pre-Tax Income Historical Data

The historical data trend for CureVac NV's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CureVac NV Pre-Tax Income Chart

CureVac NV Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Pre-Tax Income

Get a 7-Day Free Trial

-100.13

-129.85

-412.50

-249.16

-259.97

CureVac NV Quarterly Data
	Mar19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Pre-Tax Income	Get a 7-Day Free Trial															-57.42	-67.39	-48.68	-86.49	-69.89

Competitive Comparison of CureVac NV's Pre-Tax Income

For the Biotechnology subindustry, CureVac NV's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CureVac NV's Pre-Tax Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CureVac NV's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where CureVac NV's Pre-Tax Income falls into.

CureVac NV Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

CureVac NV's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-276.262	+	2.055	+	-2.493	+	16.731	+	0
	=	-259.97

CureVac NV's Pretax Income for the quarter that ended in Mar. 2024 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-74.239	+	0.922	+	-0.34	+	3.771	+	-0.00099999999999056
	=	-69.89

Pre-Tax Income for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-272.44 Mil.

CureVac NV (WBO:CVAC) Pre-Tax Income Explanation

CureVac NV's Pretax Margin for the quarter that ended in Mar. 2024 is calculated as

Pretax Margin	=	Pretax Income	/	Revenue
	=	-69.887	/	12.373
	=	-564.83%

During the past 6 years, CureVac NV's highest Pretax Margin was -265.69%. The lowest was -574.91%. And the median was -442.06%.

CureVac NV Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of CureVac NV's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.

CureVac NV (WBO:CVAC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CureVac NV (WBO:CVAC) » Definitions » Pre-Tax Income

Comparable Companies

Traded in Other Exchanges

CVAC:USA CVAC:Mexico 1CVAC:Italy 0A9E:UK 5CV:Germany

Address

Friedrich-Miescher-Strasse 15, Tubingen, BW, DEU, 72076

Website

https://www.curevac.com

CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid (mRNA). The company was founded in 2000 and had its initial public offering in August 2020. CureVac is collaborating with GlaxoSmithKline to develop a second-generation COVID-19 vaccine. CureVac's first attempt to develop a COVID-19 vaccine did not have sufficient efficacy data, and its trials were discontinued in October 2021. The company's other pipeline candidates include mRNA vaccines for influenza, rabies, and malaria. Additionally, CureVac is in the early stages of development for oncology and molecular therapies spanning tumors, liver, ocular, and lung diseases.